Insulin Detemir

證據等級: L5

預測適應症: 10 個

Insulin Detemir: From Basal Insulin Analogue to Type 1 Diabetes Mellitus

One-Sentence Summary

Insulin detemir (Levemir®) is a long-acting basal insulin analogue established globally for diabetes management, but currently unregistered with SAHPRA and unavailable in South Africa. The TxGNN model predicts it is highly effective for Type 1 Diabetes Mellitus (T1DM) — a finding consistent with its validated global clinical use — with a prediction confidence of 99.77%. This is supported by more than 10 completed Phase 3 randomised controlled trials (including trials conducted on the African continent) and 19 publications, placing the overall evidence at Level 1.

Quick Overview

Item	Content
Original Indication	Not applicable — insulin detemir has no SAHPRA-registered indication and is not currently marketed in South Africa
Predicted New Indication	Type 1 Diabetes Mellitus
TxGNN Prediction Score	99.77%
Evidence Level	L1
South Africa Market Status	Not Marketed
Number of SAHPRA Registrations	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Insulin detemir is a soluble long-acting human insulin analogue modified by attaching a C14 (myristic acid) fatty acid chain to the LysB29 residue of the insulin molecule. This modification enables reversible binding to albumin, both at the subcutaneous injection site and in the systemic circulation. The result is markedly slowed absorption and a smooth, near-peakless plasma insulin profile lasting approximately 24 hours. Once dissociated from albumin, insulin detemir binds to insulin receptors on hepatic, muscle, and adipose cells, triggering the same downstream metabolic pathways as endogenous insulin: GLUT4 translocation to the plasma membrane, hepatic glycogen synthesis, lipogenesis, and suppression of hepatic gluconeogenesis.

In Type 1 Diabetes Mellitus, autoimmune destruction of pancreatic β-cells produces an absolute deficiency of endogenous insulin. Without a basal insulin supply, fasting hyperglycaemia, protein catabolism, and diabetic ketoacidosis (DKA) rapidly ensue. Insulin detemir addresses this core pathophysiology directly — it provides the continuous, low-level insulin activity that healthy β-cells normally supply across the 24-hour period. This is not a mechanistic extrapolation; it is a pharmacologically precise match for the fundamental deficit in T1DM, making the TxGNN prediction both biologically rational and clinically expected.

Globally, insulin detemir (Levemir®, Novo Nordisk) is approved by the European Medicines Agency (EMA) and the US FDA as a first-line basal insulin for T1DM in adults, adolescents, and children from 1 year of age. Notably, one of the pivotal Phase 3 RCTs supporting this indication (NCT00447382) included South African investigational sites, meaning efficacy and safety data exist from a South African population. The drug’s absence from the SAHPRA register therefore reflects a market entry gap rather than a lack of evidence, and this report provides the evidentiary basis for a formal registration pathway.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT03220425	Phase 3	Completed	752	Large multi-centre open-label RCT comparing insulin detemir vs NPH insulin in T1DM on a once-daily basal-bolus regimen; primary evaluation of glycaemic control and safety
NCT01709929	Phase 3	Completed	2,287	Large North American multicentre non-interventional safety study evaluating insulin detemir for insulin-dependent T1DM and T2DM under routine clinical practice conditions
NCT01831765	Phase 3	Completed	1,290	52-week multinational RCT (Europe and USA) comparing faster-acting insulin aspart (FIAsp) vs insulin aspart, both in combination with insulin detemir as basal insulin, in adults with T1DM
NCT01486940	Phase 3	Completed	598	Multinational randomised parallel-group trial (Europe and South America) comparing insulin detemir + insulin aspart vs NPH insulin + human soluble insulin in T1DM on a basal-bolus regimen; demonstrated non-inferior glycaemic control with detemir
NCT00474045	Phase 3	Completed	470	Multinational RCT (Africa, Europe, Americas, Oceania) comparing insulin detemir vs NPH insulin in pregnant women with T1DM on a basal-bolus regimen; established safety and glycaemic efficacy in this high-risk population
NCT00095082	Phase 3	Completed	447	European and US trial comparing insulin detemir + aspart vs insulin glargine + aspart in T1DM; confirmed detemir as a safe and at least equally effective alternative to glargine in basal-bolus therapy
NCT00487240	Phase 3	Completed	387	Treat-to-target comparison of insulin lispro protamine suspension vs insulin detemir as basal insulin in T1DM patients on basal-bolus therapy; assessed efficacy and safety with sequential objective testing
NCT01513473	Phase 3	Completed	350	26-week multinational RCT (Africa, Asia, Europe, USA) comparing insulin degludec vs insulin detemir in children and adolescents aged 1–<18 years with T1DM on a basal-bolus regimen; detemir served as active comparator, confirming its paediatric evidence base
NCT00447382	Phase 3	Completed	330	12-month double-blind multinational RCT — including South African investigational sites — comparing two manufacturing processes of insulin detemir in T1DM; provided long-term safety data directly relevant to the South African population
NCT00595374	Phase 3	Completed	114	European RCT comparing insulin detemir + aspart vs NPH + aspart in adults with T1DM; direct head-to-head efficacy and safety comparison in a basal-bolus regimen

Literature Evidence

PMID	Year	Type	Journal	Key Findings
36623517	2023	RCT / Non-inferiority Trial	The Lancet Diabetes & Endocrinology	EXPECT trial: multinational open-label RCT comparing insulin degludec vs insulin detemir in pregnant women with T1DM; insulin detemir used as the active gold-standard comparator, confirming its established role in pregnancy
29477399	2018	Systematic Review + Network Meta-analysis	Value in Health	Assessed relative efficacy and safety of all basal insulin regimens in adults with T1DM; insulin detemir included as a primary treatment node with robust comparative data
36763996	2022	Systematic Review / Meta-analysis	Clinical Therapeutics	Compared efficacy and tolerability of insulin degludec vs insulin glargine and insulin detemir across T1DM and T2DM populations; synthesised HbA1c, hypoglycaemia, and weight outcomes
21878861	2011	Systematic Review	Polish Archives of Internal Medicine	Meta-analysis of insulin detemir vs NPH insulin specifically in T1DM; reported consistent improvement in glycaemic control and reduced nocturnal hypoglycaemia with detemir
37290466	2023	Review	The Lancet Diabetes & Endocrinology	Comprehensive update on T1DM management in pregnancy including lifestyle, pharmacological treatment, and technology; covers basal insulin analogue selection including detemir
23110609	2012	Review	Drugs	Comprehensive review of insulin detemir pharmacology, clinical efficacy, and safety across T1DM and T2DM; covers glucose-clamp studies, intrapatient variability, and weight-neutral profile
20539842	2010	Review	Vascular Health and Risk Management	Update on insulin detemir treatment for T1DM and T2DM; highlighted predictable pharmacokinetics, lower nocturnal hypoglycaemia rates, and weight advantage over NPH
17326333	2006	Review	Vascular Health and Risk Management	Review of insulin detemir’s albumin-binding mechanism and its clinical implications; summarised early trial evidence for reduced hypoglycaemia and glycaemic variability in T1DM
15516157	2004	Review	Drugs	Foundational review of insulin detemir at the time of initial regulatory approval; documented pharmacokinetic basis and pivotal trial outcomes supporting T1DM and T2DM indications
18454569	2008	Review	Paediatric Drugs	Reviewed all available insulin analogues for children and adolescents with T1DM; described insulin detemir’s pharmacokinetic advantages and safety profile in the paediatric age group

South Africa Market Information

Insulin detemir is not currently registered with SAHPRA and has no approved products available in South Africa. The table below therefore contains no entries.

Registration Number	Product Name	Dosage Form	Approved Indication
—	No SAHPRA-registered products	—	—

Note: Insulin detemir is marketed internationally as Levemir® (Novo Nordisk) in a 100 U/mL solution for injection, available as a 3 mL cartridge (Penfill®) and a 3 mL pre-filled pen (FlexPen®/FlexTouch®). It holds EMA and FDA approval for basal insulin therapy in T1DM and T2DM in adults and children from 1 year of age. Clinicians requiring access in South Africa may explore a Section 21 application (unregistered medicines) pending a formal SAHPRA registration submission. Insulin detemir is not currently included on the South African National Essential Medicines List (NEML); however, other basal insulins are included, and a registration pathway could support future NEML consideration.

Safety Considerations

Please refer to the SAHPRA-approved Professional Information (PI) for safety information. In the absence of a South African PI, clinicians should consult the EMA-approved Summary of Product Characteristics (SmPC) or the FDA-approved Prescribing Information for Levemir®, paying particular attention to hypoglycaemia risk, dose adjustment in renal or hepatic impairment, and use in pregnancy. Report any adverse drug reactions to SAHPRA via the MedSafety portal (www.sahpra.org.za).

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: Multiple large multinational Phase 3 RCTs — including trials conducted in Africa and specifically in South Africa — have established the efficacy and safety of insulin detemir for Type 1 Diabetes Mellitus at the highest evidence level (L1). The TxGNN model’s 99.77% prediction score reflects biological and clinical certainty; this is a direct pharmacological match for T1DM pathophysiology. The primary barrier to use in South Africa is regulatory (no SAHPRA registration), not evidential.

To proceed, the following is needed:

SAHPRA Registration: Submit a full dossier registration application (or Section 21 application for immediate clinical access) to SAHPRA for insulin detemir (Levemir®)
Local Professional Information (PI): Obtain SAHPRA-approved PI to confirm local labelling, safety warnings, contraindications, and drug interactions for South African prescribers
NEML and STG Alignment: Assess whether insulin detemir should be recommended within the South African Standard Treatment Guidelines (STGs) and National Essential Medicines List (NEML) for T1DM management, particularly where existing listed insulins (e.g., NPH) are suboptimal
Cold-Chain and Supply Chain Assessment: Confirm that cold-chain logistics and uninterrupted supply can be maintained across public and private healthcare sectors in South Africa
Pharmacoeconomic Analysis: Evaluate cost-effectiveness versus currently available basal insulins in the South African context, including National Department of Health tender pricing and medical scheme reimbursement
Hypoglycaemia Monitoring Protocol: Establish a clinical monitoring framework for healthcare professionals, particularly in under-resourced settings where glucose monitoring access may be limited
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.